Giuseppe Ciaramella - Dec 30, 2022 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role: President & CSO
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol: BEAM
Transactions as of: Dec 30, 2022
Transactions value $: $3,015
Form type: 4
Date filed: 1/3/2023, 03:31 PM
Previous filing: Dec 20, 2022
Next filing: Jan 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BEAM	Common Stock	Options Exercise	$3.02K	+4.5K	+4.92%	$0.67^*	96K	Dec 30, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BEAM	Stock Option (Right to Buy)	Options Exercise	$0	-4.5K	-2.3%	$0.00	191K	Dec 30, 2022	Common Stock	4.5K	$0.67	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.
F2	On April 2, 2021, the reporting person filed a Form 4 which inadvertently reported in column 9 that, following his exercise of an option, the number of derivative securities beneficially owned was 265,414 shares, when this number should have been reported as 253,414 shares. This Form 4 reflects the corrected number of derivative securities beneficially owned following the transactions reported since April 2, 2021, including the transaction reported herein.

Content

The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

On April 2, 2021, the reporting person filed a Form 4 which inadvertently reported in column 9 that, following his exercise of an option, the number of derivative securities beneficially owned was 265,414 shares, when this number should have been reported as 253,414 shares. This Form 4 reflects the corrected number of derivative securities beneficially owned following the transactions reported since April 2, 2021, including the transaction reported herein.